MedPage Today October 13, 2025
Elecsys pTau181 test can help rule out Alzheimer’s-related amyloid pathology
FDA cleared the Elecsys pTau181 test as the first blood-based biomarker to aid in the initial assessment of Alzheimer’s disease and other causes of cognitive decline that can be used in the primary care setting, Roche announced on Monday.
The test measures plasma levels of phosphorylated tau 181 (p-tau181), one of the key markers of amyloid plaque and tau aggregate pathology behind Alzheimer’s disease, and is intended for patients 55 and older who present with signs, symptoms, or complaints of cognitive decline to rule out Alzheimer’s-related amyloid pathology in conjunction with other clinical information.
“By enabling use in primary care, the Elecsys pTau181 test has the potential to significantly broaden...
Today's Sponsors
Today's Sponsor